Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
238.59
+10.59 (4.64%)
At close: Jun 23, 2026, 4:00 PM EDT
238.95
+0.36 (0.15%)
After-hours: Jun 23, 2026, 6:21 PM EDT
Ascendis Pharma Employees
Ascendis Pharma had 1,189 employees as of December 31, 2025. The number of employees increased by 172 or 16.91% compared to the previous year.
Employees
1,189
Change (1Y)
172
Growth (1Y)
16.91%
Revenue / Employee
$839,568
Profits / Employee
$480,917
Market Cap
14.82B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,189 | 172 | 16.91% |
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Dec 31, 2022 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | 330 | 114 | 52.78% |
| Dec 31, 2018 | 216 | 79 | 57.66% |
| Dec 31, 2017 | 137 | 36 | 35.64% |
| Dec 31, 2016 | 101 | 23 | 29.49% |
| Dec 31, 2015 | 78 | 23 | 41.82% |
| Dec 31, 2014 | 55 | 10 | 22.22% |
| Dec 31, 2013 | 45 | 7 | 18.42% |
| Dec 31, 2012 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 3,088 |
| Jazz Pharmaceuticals | 2,890 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| BridgeBio Pharma | 839 |
ASND News
- 10 days ago - Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism - GlobeNewsWire
- 12 days ago - 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism - GlobeNewsWire
- 15 days ago - Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 - GlobeNewsWire
- 6 weeks ago - Ascendis Pharma Earnings Call Transcript: Q1 2026 - Transcripts
- 6 weeks ago - Ascendis Pharma Earnings release: Q1 2026 - Filings
- 6 weeks ago - Ascendis Pharma Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 6 weeks ago - New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years - GlobeNewsWire
- 7 weeks ago - Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 - GlobeNewsWire